Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company
and a leader in the treatment of cardiovascular diseases, announced
today the first world implant of its CROWN PRT bioprosthetic aortic
valve. The implant was performed in Austria at the Salzburg University
Clinic by Prof. Rainald Seitelberger, M.D., and Christian Dinges, M.D.
"Our first experience with CROWN PRT has been extremely positive," said
Professor Seitelberger. "The short two-minute rinse time proved very
convenient to streamline intraoperative handling and save on aortic
clamp time. The visible commissural markers and the smooth sewing cuff
facilitated valve suturing into position. The valve adapted perfectly to
the aortic annulus ensuring excellent stability."
"During the implant, CROWN PRT demonstrated very good pressure gradients
as measured by transesophageal echocardiography," continued Professor
Seitelberger. "A meaningful number of implantations will be required to
thoroughly assess the valve's overall performance. However, this first
implant is very promising."
CROWN PRT is the latest advancement in stented aortic bioprosthesis
technology, featuring surgeon-friendly design, optimal hemoynamics and
the patented Phospholipid Reduction Treatment (PRT) to bolster
durability through mitigation of calcium uptake1.
"The CROWN PRT implant performed by Professor Seitelberger and his team
represents a key successful step to strategically grow our presence in
the tissue heart valve segment worldwide," said Michel Darnaud,
President, Cardiac Surgery Business Unit, Sorin Group. "The most
rewarding aspect of this implant is to see Sorin's innovative technology
deliver on its promise of greater standards both for physicians and
1. Based on 60-day animal model. Sorin Group 2014. Data on file.
About Sorin GroupSorin Group (www.sorin.com)
is a global medical device company and a leader in the treatment of
cardiovascular diseases. The Company develops, manufactures, and markets
medical technologies for cardiac surgery and for the treatment of
cardiac rhythm disorders. With over 3,500 employees worldwide, Sorin
Group focuses on two major therapeutic areas: Cardiac Surgery
(cardiopulmonary products for open heart surgery and heart valve repair
or replacement prostheses) and Cardiac Rhythm Management (pacemakers,
defibrillators and non invasive monitoring to diagnose arrhythmias and
deliver anti-arrhythmia therapies as well as cardiac resynchronization
devices for heart failure treatment). Every year, over one million
patients are treated with Sorin Group devices in more than 100 countries.
For more information, please visit www.sorin.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140902005413/en/
[ Back To NFVZone's Homepage ]